<?xml version='1.0' encoding='utf-8'?>
<document id="18000659"><sentence text="The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition."><entity charOffset="36-45" id="DDI-PubMed.18000659.s1.e0" text="erlotinib" /></sentence><sentence text="Erlotinib is an orally active antitumor agent"><entity charOffset="0-9" id="DDI-PubMed.18000659.s2.e0" text="Erlotinib" /></sentence><sentence text=" Analyses in vitro using human liver microsomes and recombinant enzymes showed that erlotinib was metabolized primarily by CYP3A4, with a secondary contribution from CYP1A2"><entity charOffset="84-93" id="DDI-PubMed.18000659.s3.e0" text="erlotinib" /></sentence><sentence text="" /><sentence text="A computer-based simulation model, SimCYP, predicted that CYP3A4 contributed to approximately 70% of the metabolic elimination of erlotinib, with CYP1A2 being responsible for the other approximately 30%"><entity charOffset="130-139" id="DDI-PubMed.18000659.s5.e0" text="erlotinib" /></sentence><sentence text=" A drug-drug interaction study was therefore conducted for erlotinib and a potent CYP3A4 inhibitor, ketoconazole, in healthy male volunteers to evaluate the impact of CYP3A4 inhibition on erlotinib exposure"><entity charOffset="59-68" id="DDI-PubMed.18000659.s6.e0" text="erlotinib" /><entity charOffset="100-112" id="DDI-PubMed.18000659.s6.e1" text="ketoconazole" /><entity charOffset="188-197" id="DDI-PubMed.18000659.s6.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.18000659.s6.e0" e2="DDI-PubMed.18000659.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18000659.s6.e0" e2="DDI-PubMed.18000659.s6.e1" /><pair ddi="false" e1="DDI-PubMed.18000659.s6.e0" e2="DDI-PubMed.18000659.s6.e2" /><pair ddi="false" e1="DDI-PubMed.18000659.s6.e1" e2="DDI-PubMed.18000659.s6.e1" /><pair ddi="false" e1="DDI-PubMed.18000659.s6.e1" e2="DDI-PubMed.18000659.s6.e2" /></sentence><sentence text="" /><sentence text="Ketoconazole caused an almost two-fold increase in erlotinib plasma area under the concentration curve and in maximum plasma concentration"><entity charOffset="0-12" id="DDI-PubMed.18000659.s8.e0" text="Ketoconazole" /><entity charOffset="51-60" id="DDI-PubMed.18000659.s8.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.18000659.s8.e0" e2="DDI-PubMed.18000659.s8.e0" /><pair ddi="false" e1="DDI-PubMed.18000659.s8.e0" e2="DDI-PubMed.18000659.s8.e1" /></sentence><sentence text=" This is consistent with the SimCYP prediction of a two-fold increase in erlotinib AUC, further validating a primary (approximately 70%) role of CYP3A4 in erlotinib elimination"><entity charOffset="155-164" id="DDI-PubMed.18000659.s9.e0" text="erlotinib" /></sentence><sentence text="" /><sentence text="Prediction of clinically important drug-drug interaction with SimCYP using in vitro human metabolism data can be a powerful tool during early clinical development to ensure safe administration of anticancer drugs, which are often co-administered at maximum tolerated doses with other drugs as part of a palliative treatment regimen" /><sentence text="" /></document>